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ABSTRACT
The master tumor suppressor p53 controls tran-
scription of a wide-ranging gene network involved in
apoptosis, cell cycle arrest, DNA damage repair, and
senescence. Recent studies revealed pervasive bind-
ing of p53 to cis-regulatory elements (CREs), which
are non-coding segments of DNA that spatially and
temporally control transcription through the com-
binatorial binding of local transcription factors. Al-
though the role of p53 as a strong trans-activator of
gene expression is well known, the co-regulatory fac-
tors and local sequences acting at p53-bound CREs
are comparatively understudied. We designed and
executed a massively parallel reporter assay (MPRA)
to investigate the effect of transcription factor bind-
ing motifs and local sequence context on p53-bound
CRE activity. Our data indicate that p53-bound CREs
are both positively and negatively affected by alter-
ations in local sequence context and changes to co-
regulatory TF motifs. Our data suggest p53 has the
flexibility to cooperate with a variety of transcription
factors in order to regulate CRE activity. By utilizing
different sets of co-factors across CREs, we hypoth-
esize that global p53 activity is guarded against loss
of any one regulatory partner, allowing for dynamic
and redundant control of p53-mediated transcription.
INTRODUCTION
The master tumor suppressor p53 is a transcription fac-
tor with key roles in preserving genome idelity and cellular
homeostasis. In support of these activities, p53 regulates a
core transcriptional program involved in cellular processes
like cell cycle arrest, apoptosis, DNA repair, and senescence
(1–3). Loss of p53 activity is strongly linked to increased
cancer risk and decreased life expectancy, andmisregulation
of p53 is associated with numerous other human disorders.
Recent analyses suggest that p53 is mutated in greater than
30% of cancer cases and the majority of p53 variants are
unable to bind DNA and enact a tumor suppressive gene
expression program (4). The mechanisms by which tumori-
genesis progresses in the presence of wild type p53 activ-
ity have not been well characterized. Recent evidence sug-
gests that sequence variation within cis-regulatory elements
(CREs) can inluence p53 binding, transcriptional activity,
and tumor suppressor function (5–7). The critical nature
of the core p53 response element (p53RE) on p53 binding
and CRE activity is well understood (8–10), but the inlu-
ence of local sequence variation and the role of additional
transcription factor motifs within a CRE on p53 activity
remains an open and vital question.
Cis-regulatory elements, such as promoters and en-
hancers, govern gene expression through temporal, spa-
tial, and quantitative control of transcription (11,12).While
multiple models for CRE function have been proposed, the
majority involve cooperative binding of transcription fac-
tors and cofactors acting locally to ine-tune gene expres-
sion (11–13). The presence and availability of transcrip-
tion factors, repressors, and other cofactors vary across cell
states such as development, stress, disease, and cell type
(14–17). This variability provides a mechanism for differ-
ential CRE activity and downstream gene expression. Loss
of transcription factor binding, through variation in DNA
sequence or through changes in trans-factor availability,
can strongly inluence CRE activity and gene expression
(11,12,18), with direct implications in numerous develop-
mental and disease states (14,16).
While general transcription factors, like the TFIID com-
plex (19,20), are involved in p53-dependent trans-activation
at promoters, the requirement for other sequence-speciic
trans-factors at distally-acting CREs is unknown. A novel
model was recently proposed whereby binding of a single
transcription factor, in this case p53, was necessary and
suficient for CRE activity (9). This model was supported
by another study suggesting that a canonical p53 response
element (p53RE) is the only sequence-based determinant
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of p53-dependent CRE activity (10). However, multiple
p53-dependent CREs have been reported to require other
locally-acting transcription factors, in line with established
CRE mechanisms like the enhanceosome and billboard
models (18,21). For example, CRISPR/Cas9-based screen-
ing identiied a CEBP-binding site within a CRE regulat-
ing CDKN1A/p21 required for p53-dependent senescence
(22). Transcription factors such as those in the AP-1 fam-
ily and SP1 have also been implicated in the activation of
p53-dependent gene targets (23–25).
In order to directly address whether additional cofac-
tors are required for p53-dependent transcriptional activ-
ity, we examined the effect of local sequence variation on
putative p53 CREs using a massively parallel reporter as-
say (MPRA). Our results suggest that sequences lanking
p53REs and transcription factors other than p53 are re-
quired for p53-dependent transcriptional activation. Con-
sistent with previous reports, the p53RE is a strong deter-
minant of p53-inducible activity. Loss of p53 occupancy
through sequence manipulation or depletion of the pro-
tein strongly reduces CRE activity. We also identiied se-
quences outside of the p53RE that positively or negatively
regulate transcription. This includes a conserved SP1/KLF
family binding site required for optimal transcription of the
p53-dependent gene CCNG1 (cyclin G1). We also identi-
ied two distinct CREswith different local transcription fac-
tor requirements that are both necessary for p53-dependent
transcriptional activation of GDF15, a gene recently identi-
ied as a key mediator of inlammation and metabolic func-
tion (26,27). Thus, p53-bound CREs do not depend on just
one family of transcription factors for activity and can uti-
lize multiple and different factors to regulate transcription.
Thus, these data indicate p53’s lexibility to collaborate with
different combinations of locally available transcription fac-
tors to regulate CRE activity and downstream gene activa-
tion involved in key organism-level traits like tumor sup-
pression.
MATERIALS AND METHODS
Cell culture
HCT116 parental, TP53−/− andATF3−/− lines were cul-
tured in McCoy’s 5A media with 10% fetal bovine serum.
HCT116 ATF3−/− cell line was a kind gift of Chunhong
Yan (Augusta University) (28). MCF10A cells were grown
in HuMEC media (Gibco). Mouse embryonic ibroblasts
(MEFs) were grown in DMEM with 10% FBS and were a
kind gift of Jing Huang (National Cancer Institute, NIH).
All cell lines were cultured at 37◦C and 5% CO2 in a water-
jacketed incubator.
Selection of candidate enhancers
Candidate enhancer regions were selected start-
ing with regions of the hg19 genome assembly
containing DNAse Hypersensitive Sites (DHS)
(wgEncodeRegDnaseClusteredV3 downloaded from
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/
encodeDCC/wgEncodeRegDnaseClustered/). DHS were
then iltered by the presence of a p53 family motif using
gimmeMotifs (29). Ultimately, 296 DHS containing a p53
family motif and falling within 100 kb of a coding sequence
transcriptional start site (TSS) were randomly selected
for MPRA analysis. In parallel, 196 enhancers from the
FANTOM Ubiquitous Enhancer group were selected
as positive controls, with the central 100 bp segment of
each enhancer used in the MPRA (http://enhancer.binf.
ku.dk/presets/Ubiquitous enhancers S9.bed). Candidate
p53-bound enhancers were shortened to 100 bp with the
20 bp p53 response element motif at the center with 40 bp
of lanking genomic context on each side. Each candidate
p53-bound enhancer was scrambled in 20 bp sections from
5′ to 3′ across the entire length producing. Nucleotide
randomization preserved GC content and was performed
using EMBOSS shufleseq (30). As negative controls for
regulatory activity, the entire 100 bp sequence for all
candidate or ubiquitous enhancers was scrambled while
preserving GC content.
Massively Parallel Reporter Assay (MPRA) oligo design
Our MPRA was designed using a previously published
method (31). In brief, each candidate 100 bp regulatory se-
quence was coupled to ive separate 12 nucleotide unique
molecular identiier (UMI) sequences. Replicates of the test
sequences plus controls totaled the library at 12 035 unique
oligos in the orientation of: a 5′ Primer binding overlap, a
100 bp enhancer sequence, a spacer for restriction enzyme
sites EcoRI and SbfI, a unique enhancer associated 12 bp
barcode, and a 3′ Primer binding overlap. All sequences for
the MPRA oligo library are found in Supplemental Table
S1. The inal 12 035 unique oligo pool was synthesized by
CustomArray.
Two-step vector library cloning and veriication
TheMPRA lentiviral vector pLs-mP was a gift fromNadav
Ahituv (Addgene plasmid # 81225; http://n2t.net/addgene:
81225; RRID:Addgene 81225). pLs-mP was digested with
the restriction enzymes EcoRI and SbfI yielding two frag-
ments representing the plasmid backbone and the minimal
promoter/eGFP. The candidate enhancer pool was PCR
ampliied using primers SL468 and SL469 in 3 separate re-
actions of 50 ng at 21 cycles each, gel puriied, and com-
bined (Supplemental Table S2, cloning primers tab). The
resulting PCR product was ligated to the EcoRI–SbfI di-
gested pLs-mP backbone in three separate Gibson assem-
bly reactions (HiFi DNA Assembly, NEB). 2 l of each
Gibson assembly reaction were transformed into Stbl4 elec-
trocompetent Escherichia coli (Invitrogen) in three separate
transformation reactions (1200 V, 200 , BioRad). Trans-
formation reactions were plated on 10 separate 15 cm LB-
agar plates with 100 ug/ml ampicillin selection at 30◦C
for 48 h. Colonies were isolated directly from plates and
plasmid DNA was individually prepped (ZymoPURE II
Midi Plasmid Kit). The resulting DNA was combined to
create the Step 1 library. This plasmid pool was then di-
gested with EcoRI and SbfI in three separate reactions at
1 g each and gel puriied. The 780 bp fragment from
the original EcoRI–SbfI reaction (containing the minimal
promoter/EGFP fragment), was ligated into the digested
Step 1 plasmid using T4 ligase. Ligation products were
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transformed as above and the resulting MPRA library was
sequence veriied by Illumina sequencing.
MPRA virus production and transduction
HEK293FT cells were used for virus preparation and were
cultured in DMEM with 10% FBS without antibiotic. To
make virus, 4 × 106 cells were seeded in 10 cm plates 24 h
before transfection. Per 10 cm plate, cells were transfected
with 8 ug of MPRA lentiviral backbone, 4 ug of M2G
helper plasmid and 8ug of ps-PAX helper plasmid using Jet-
Prime transfection reagent according tomanufacturer’s rec-
ommendations. Virus was collected from supernatant at 24
and 48 h, pooled, and iltered using 0.45 m syringe ilters.
HCT116 TP53+/+ and TP53−/− cell lines were seeded 24 h
before viral transduction in three 10 cm plates at a concen-
tration of 2.0× 106 cells/plate. Virus supernatant was com-
bined with 8 g/ml polybrene, added to the seeded cells,
and incubated for 48 h. Cells were then treated for 6 h with
DMSO (as a control) or 5 M Nutlin-3A (45-SML0580,
Millipore Sigma) to induce p53 activity. One plate was left
untreated as the infection control plate for genomic DNA
isolation. After 6 h of treatment, cells were collected in ice-
cold 1× PBS, snap-frozen on liquid nitrogen, and stored at
−80◦C until analysis. Three biological replicates were per-
formed for each condition.
Amplicon enrichment and RNA-seq library preparation
Total RNA was isolated from DMSO or Nutlin-3A treated
cells (EZ RNAKit, Omega Biotek) with on-column DNA-
seI treatment. 6 ug of resulting total RNA was then taken
through an additional round of TurboDNase treatment
(ThermoFisher) to ensure complete removal of contami-
nating genomic DNA. The resulting RNA was split into
three irst strand reverse transcription reactions each us-
ing custom barcoded primers to identify the cell line, treat-
ment, and replicate number (Supplemental Table S2, Bar-
code primers tab). All three cDNA reactions were com-
bined and taken through a two-step PCR ampliication
process. In Round 1, each cDNA sample was ampliied
in 22 separate PCR reactions of three cycles each us-
ing barcoded primers (Supplemental Table S2). PCR reac-
tions were then pooled and puriied using 2.5× AMPure
XP beads (Beckman-Coulter). The puriied Round 1 PCR
product went through a second round of PCR in eight reac-
tions for 15 cycles each using barcoded primers as described
in Supplemental Table S2. Step 2 PCR product was run on
a 2% agarose gel and gel puriied. Genomic DNA controls
were prepared in a similar manner. 500 ng of genomic DNA
was PCR ampliied across 16 separate reactions of three cy-
cles each using barcoded primers described in Supplemen-
tal Table S2. The pooled PCR product was combined and
puriied using 2.5× volume AMPure XP beads. The result-
ing puriied DNAwas then separated into 16 separate PCR
reactions of 15 cycles each, pooled, and gel puriied. After
the two-step PCR reaction, DNA amplicons representing
the expressed mRNA barcode and the genomic DNA in-
fection control within each biological replicate were com-
bined at equal molarity. An Illumina-compatible sequenc-
ing library was generated (NEBNext Ultra II DNALibrary
Kit, New England Biolabs) for each biological replicate and
sequenced using the NextSeq 500 at the University at Al-
bany Center for Functional Genomics.
Massively Parallel Reporter Assay (MPRA) data analysis
Sequencing reads for each individual experimental condi-
tion were lanked by a unique 5′ and 3′ amplicon bar-
code to allow separation from the pooled raw sequenc-
ing reads. Barcoded, experimental condition-speciic reads
were separated into individual iles for further analysis using
the FastX toolkit (fastx-barcode-splitter, http://hannonlab.
cshl.edu). Barcodes for within-pool sequence identiication
can be found in Supplemental Table S2 (barcode primers
tab). The number of reads containing unique enhancer
identifying sequences were then parsed and counted using
fastX-collapser from the FastX-toolkit. Raw read counts
for each enhancer sequence across cell lines, treatment con-
ditions, and biological replicates be found in Supplemental
Table S3. Differential enhancer activity across experimental
conditions and cell lines was calculated from raw enhancer
barcode read counts using DESeq2 (32). To account for dif-
ferences in representation across the original viral enhancer
sequence library, raw enhancer barcode read counts scaled
to transcripts per million (TPM) and were then normalized
to the read counts from genomic DNA (fold-change, RNA
barcode/ DNA barcode). Normalized enhancer count val-
ues for mutant enhancer sequences were then compared to
wild-type values using a one-way ANOVA with a post-hoc
Tukey HSD test implemented in R (33).
In vivo CRISPR/Cas9 mutagenesis and amplicon ChIP-
sequencing
HCT116 colon carcinoma cells were transduced with
lentiCas9-Blast and cells stably expressing wild-type spCas9
were selected using 2 g/ml blasticidin. LentiCas9-Blast
was a gift from Feng Zhang (Addgene plasmid #52962;
http://n2t.net/addgene:52962; RRID:Addgene 52962).
Streptomyces pyogenes (sp) guide RNA sequences (Sup-
plemental Table S2) were cloned into the LentiGuide-Puro
plasmid (plasmid #52963, Addgene). lentiGuide-Puro
was a gift from Feng Zhang (Addgene plasmid # 52963;
http://n2t.net/addgene:52963; RRID:Addgene 52963).
Both LentiGuid-Puro and LentCas9-Blast were originally
published in (34). Viral particles from LentiGuide-Puro
were made by transfecting HEK293FT cells with the pack-
aging plasmids psPax2 and pMD2.G and the respective
guide RNA viral backbone cloned into pLS-mP. psPAX2
was a gift from Didier Trono (Addgene plasmid # 12260;
http://n2t.net/addgene:12260; RRID:Addgene 12260).
pMD2.G was a gift from Didier Trono (Addgene
plasmid # 12259; http://n2t.net/addgene:12259;
RRID:Addgene 12259).
HCT116 cells stably expressing spCas9 were selected with
2 g/ml puromycin 48 h after infection. The heterogenous
cell pool was then treated for 6 h with either DMSO or
5 M Nutlin-3A for either qPCR-mediated gene expres-
sion measurements or for ChIP. For ChIP, 10 million cells
were crosslinked on plate with 1% formaldehyde for 10 min
at room temperature until the reaction was quenched with
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2.5% glycine. Crosslinked cells were processed using stan-
dard lysis procedures and chromatin was sonicated using
a probe sonicator (Qsonica) at 25% amp for 10 pulses to-
tal; 10 seconds on, 50 s off for a total of 10 min at 4◦C.
Sheared chromatin was then used in a ChIP assay for p53
(clone DO1, BD Biosciences). 50 ng of puriied DNA per
experimental sample was used in a barcoding PCR reac-
tion (Supplemental Table S2, barcode primers tab), and
amplicons were then used as template for created Illumina-
compatible sequencing libraries (NEBNext Ultra II DNA
Library Kit). Libraries were quantiied by qPCR and run
on an IlluminaNextSeq 500 (150 bp single-end). RawFastQ
reads containing the amplicon primers (Supplemental Ta-
ble S2, barcode primers tab) were iltered (fastx-barcode-
splitter, FastX-toolkit, http://hannonlab.cshl.edu) and used
in subsequent analysis. The number of reads per DNA vari-
ant were quantiied (fastX-collapser, FastX-toolkit) and the
ChIP values were normalized to genomicDNA input.DNA
variants were then sorted by the presence or absence of p53
or Sp1/KLF family motifs as determined by gimmeMotifs
(29). Data tables for the amplicon ChIP-seq experiment can
be found in Supplemental Table S4.
Quantitative real time PCR
Total RNA was isolated using the Omega E.Z RNA kit
with an on-column treatment with 50 units of RNAse-free
DNase I for 30 min. Single-stranded cDNA was gener-
ated with the High Capacity cDNA Reverse Transcription
reagents (Applied Biosystems), and qPCR was performed
on an Applied Biosystems 7900H with the relative standard
curve method and iTaq Universal SYBR Green Supermix
reagents (Biorad). qPCR primers are shown in Supplemen-
tal Table S2 (qPCR tab).
Chromatin immunoprecipitation for histone modiications
HCT116 colon carcinoma cells were treated for 6 h with
5uM Nutlin-3A and then crosslinked with methanol-free
formaldehyde (1% inal) at room temperature for 5min. The
reaction was then quenched with 2.5 M glycine for 5 min,
followed by two washes with ice-cold PBS. Nuclear extrac-
tion and sonication were performed as previously described
(35), with an average fragment size of 500 bp. Crosslinked
material was then immunoprecipitated with 5 ug of ei-
ther anti-H3K27ac (Active Motif 39133) or anti-H3K4me2
(Millipore 07-030) coupled to Protein A/GDynabeads (In-
vitrogen) overnight at 4◦C. Beads were then washed 3×
with low-salt buffer, 1× with high-salt buffer, and 1× with
LiCl buffer, followed by elution with 1% SDS and 500 mM
NaCl at 65◦C with shaking (35). Eluted DNA was then
quantiied and used for Illumina-compatible library prepa-
ration using the New England Biolabs NEBNext Ultra II
DNA Library prep reagents. Libraries were sequenced on
an Illumina NextSeq 500. Raw data were aligned to the
human hg19 genome assembly using hisat2 (36). DNAse-
seq, H3K4me1 and H3K4me3 histone modiication data
were obtained from the ENCODE Reference Epigenome
Series for HCT116 colon carcinoma cell lines under ac-
cession ENCSR309SGV. eRNA data were obtained from
GEO GSE53966 (2) and GEO GSE86165 (1). Normalized
read counts within MPRA region coordinates were quanti-
ied using HOMER (37).
Luciferase plasmid cloning and expression assays
Candidate enhancer sequences were synthesized as dsDNA
(IDT) and cloned into the pGL4.24 destabilized Luciferase
reporter vector (Promega) using the HiFi DNA Assem-
bly method (NEB). Enhancer variants were created us-
ing the inverse PCR method with Hot Start Q5 Poly-
merase (NEB) and primers available in Supplemental Ta-
ble S2. Plasmids were reverse transfected according to man-
ufacturer’s recommendations (JetPrime, Polyplus Trans-
fection) in triplicate in a 96-well plate. Plasmid DNA
(0.2 g) was transfected at a ratio of 9:1 for the candidate
enhancer:constitutive promoter driving Renilla luciferase
(pGL4.75, Promega). Luciferase activity was determined
using the Promega Dual-Luciferase® Reporter Assay Sys-
tem according to manufacturer speciications on a Synergy
HI plate reader (Bio-Tek).
Western blotting
Total protein was isolated using RIPA buffer, followed
by a 15-min incubation on ice, and pelleting of and cen-
trifugation to remove insoluble debris. Protein lysate sam-
ples were run at 180 V on NuPAGE 10% Bis–Tris pro-
tein gels from Invitrogen. Samples were blotted onto 0.2
m nitrocellulose membrane and probed with p53 (clone
DO1, BD Biosciences, #554923) or GAPDH (Cell signal-
ing #5174S) antibodies. Proteins were visualized withHRP-
conjugated secondary antibodies and SuperSignal Chemi-
luminescent reagents (Thermo Scientiic) and imaged on a
BioRad Chemidoc imager.
Protein expression and puriication
Human p531–393 in pGEX-2TK (Ampicillin) coding for an
in-frameN-terminalGST tagwas a gift fromCherylArrow-
smith (Addgene plasmid # 24860; http://n2t.net/addgene:
24860; RRID:Addgene 24860 and (38)). p531–393 was ex-
pressed in Rosetta 2 DE3 cells (EMDMillipore) in 2YTme-
dia. Cells were grown at 37◦C with shaking at 225 rpm un-
til OD600 nm = 0.4–0.6, then shifted to 22
◦C and induced
with 1 mM IPTG for 4 h. Cells were harvested by centrifu-
gation at 4800 rpm for 15 min. Cell pellets were lysed in
GST Buffer A (20 mM Tris–HCl pH 7.3 (RT), 300 mM
NaCl, 0.2 mM EDTA, 1 mM DTT, 5% glycerol, 10 mM
Na-butyrate and supplemented with Complete protease in-
hibitor cocktail (Roche) and 0.1% NP40. Cells were lysed
by sonication. Cell lysates were cleared by centrifugation at
18 000 rpm for 45 min at 4◦C. Cell lysates were iltered with
a 0.45 uM syringe ilter and loaded on to an equilibrated 5
ml GSTrap HP column (GEHealthcare) using an Akta Pu-
riier FPLC (GEHealthcare). The column was washed with
GST Buffer A; bound protein was eluted using a linear gra-
dient of 0–100%GSTBuffer B (GSTBufferA+ 10mMglu-
tathione (reduced)). Purity was determined by SDS PAGE
using a 4–12% Bis–Tris gel run in 1× MOPS SDS buffer.
Eluted fractions containing p531–393 constructs were pooled
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and concentrated using a Vivaspin 10 kDa MWCO cen-
trifugal concentrator (GE healthcare). Concentrated pro-
tein was dialyzed overnight intoGST-BufferD (GSTBuffer
A + 20% glycerol). Protein concentration was determined
using a nanodropwith calculated extinction co-eficient and
molecular weight parameters. Puriied protein was divided
into single use aliquots, lash frozen in liquid nitrogen and
stored at −80◦C.
CCNG1 p53 electrophoretic mobility shift assay
Binding of p53 to CCNG1 enhancer sequences was tested
by electrophoretic mobility shift assays (EMSAs). 60 bp
HPLC puriied DNA sequences (IDT, Supplemental Ta-
ble S2, EMSA tab) were resuspended at 100 M in 1× TE
buffer. Equal volumes of complementary oligonucleotides
were heated at 95◦C for 5 min and annealed by cooling
to 21◦C for 30 min. Binding reactions were assembled in
DNase/RNase free, low adhesion microcentrifuge tubes.
Reactions contained 1× p53 binding buffer (50 mM Tris–
HCl pH 7.3, 150 mM NaCl, 2 mM DTT, 0.1 mg/ml BSA).
Unless otherwise stated, 50 nM of annealed DNA was
added to each reaction. Binding reactions were started by
adding the required concentration of p531–393 and allowed
to proceed for 30min at 21◦C.Reactions were loaded imme-
diately on a vertical 0.7% Agarose gel (Ultrapure agarose,
Life Technologies) buffered with 1×TBE.Gels were run for
45 min at 60 V in 1× TBE buffer. Gels were stained for 10
min with 1× SYBR gold nucleic acid stain (ThermoFisher)
in 1× TBE buffer and imaged on a G:box blue light tran-
silluminator (Syngene). Densitometric analysis was carried
out in Fiji (39); binding curves were itted using the Hill
equation with a two-site binding model (Hill coeficient =
2) using non-linear regression (nls) in R (33).
RNA sequencing
HCT116 parental, TP53−/− or ATF3−/− cells were
treated at 80% conluency in a six-well plate with either
DMSO or 5 MNutlin-3A for 6 h and total RNA was iso-
lated (EZ RNA, Omega Biotek). PolyA+ RNA was puri-
ied using poly dT magnetic beads (Perkin Elmer) and frag-
mented at 90◦C for 15 min. Fragmented RNA was used
as the template for double-stranded cDNA production us-
ing random hexamers (irst strand synthesis) and the dUTP
method to preserve strandedness (second strand synthe-
sis). The resulting double-stranded cDNA was then used to
construct an Illumina-compatible sequencing library (BioO
NextFlex RNA Library Kit, Perkin Elmer). Libraries were
quantiied using qPCR (NEBNext Library Quantiication,
NewEnglandBiolabs) and anAgilent Bioanalyzer and then
pooled for sequencing on an Illumina NextSeq 500. Se-
quencing reads were aligned to the hg19/GRCh37 assembly
and transcript counts were determined using quantMode
in STAR (40). Differential gene expression and normalized
gene counts were determined using DESeq2 (32).
Transcription factor peak intersections
Transcription factor peak iles were obtained from the
Cistrome database ((41), http://cistrome.org/db, accessed 1
July 2019). MPRA regions were converted into the hg38
genome assembly coordinates using liftOver from hg19
to hg38 (UCSC). Transcription factor peak summits were
then intersected withMPRA regions using BedTools (inter-
sectBed) (42). Peak intersection data were clustered by row
(MPRA regions) and column (transcription factor) by One
minus Pearson Correlation with complete linkage using
Morpheus (https://software.broadinstitute.org/morpheus).
Data underlying the cluster analysis can be found in Sup-
plemental Table S5.
Transcription factor motif analysis
Three tools were used to identify motifs either present or
enriched within the 100 bp regions from the MPRA p53-
bound and p53-unbound peaks. Additionally, we analyzed
transcription factor motif presence and enrichment within
a set of p53 binding sites identiied across multiple cell types
in Verfaillie et al. (9). For the Verfaillie p53 set, we con-
sidered only the 1001/1149 (87%) p53 peaks found within
DNAse Hypersensitive Clusters (UCSC GenomeBrowser,
ENCODE Regulation Track (43,44)). Motif analysis was
then performed on the entire DNAse Hypersensitive Clus-
ter region. Known Motif enrichment using HOMER (37)
was performed using the indMotifsGenome module (ind-
MotifsGenome.pl -nomotif -size given) against the hg19
genome. Analysis for the presence of known motifs within
MPRA regions and the Verfaillie p53 set was performed
using the 2018 release of JASPAR Vertebrate Transcrip-
tion Factor Motif Database (45) and both gimmeMo-
tifs (29) and UCSC TableBrowser (46). Analysis of tran-
scription factor motif enrichment using gimmeMotifs was
run using the scan module (options -t -g hg19 -p JAS-
PAR2018 vertebrates.pfm). The presence of hg19-based
JASPAR vertebrate transcription factor motifs within p53-
bound MPRA peaks and within the Verfaillie p53 set was
performed using the UCSC TableBrowser and the JASPAR
2018 hg19TrackHub.Onlymotifs with an enrichment score
of 400 or higher (P < 0.0001) were considered for analysis.
Histograms of motif enrichment within MPRA p53 or Ver-
faillie p53 peak sets were generated using bedTools (cover-
ageBed -d option) and Morpheus.
Sequencing data availability
All sequencing data generated as part of this manuscript
are available under Gene Expression Omnibus (GEO) Ac-
cessionGSE137297. p53ChIP data fromNutlin-3A-treated
cells were obtained fromGSE86222 (1). Conserved element
data (bigWig) from PhyloP (47) and PhastCon (48) were
obtained from the UCSC Genome Browser and plots were
generated using deepTools (49).
RESULTS
Design and execution of a massively parallel reporter assay
for determinants of p53-dependent CRE activity
We designed a barcoded and chromosomally integrated re-
porter system to assess the function of DNA sequences
lanking the p53RE in p53-dependent CREs (Figure 1A).
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Figure 1. (A) Schematic andworklow for amassively parallel reporter assay (MPRA) to study the effect of lanking sequence context on p53 transcriptional
activity. Heatmaps of p53 ChIP-seq enrichment fromNutlin-3A-treated HCT116 colon carcinoma cell lines for (B) p53-bound or (C) p53-unbound regions
found in the MPRA pool. (D) DNA sequence weight motifs for p53-bound (top) or unbound (bottom) regions from the MPRA pool. (E) Jitter plot of
scores from p53scan depicting the adherence to a canonical p53 family motif sequence for the p53-bound and p53-unbound regions. Enrichment of
(F) H3K27ac or (G) H3K4me2 in Nutlin-3A-treated HCT116 cells at p53-bound or unbound regions. Statistics represent an unpaired, two-tailed t-test
(***P < 0.001, ****P < 0.0001). (H) eRNA enrichment measured by GRO-seq in p53-bound versus p53-unbound regions (±250 bp from p53 response
element/p53RE). Statistics represent an unpairedMann–WhitneyU test (***P< 0.001). (I) Normalized transcriptional activity of p53-bound or unbound
regions from the MPRA assay after 6 h of either DMSO or 10 uM Nutlin-3A treatment. Data are depicted as enrichment of the 3′UTR-encoded barcode
linked to each putative regulatory region normalized to the enrichment of that same sequence integrated into the genome and represent the averages
from three biological replicates of each condition (****P < 0.0001 by one-way ANOVA). (J) eRNA fold-change (Nutlin-3A versus DMSO conditions) as
measured by GRO-seq at p53-bound versus p53-unbound regions. Statistics represent an unpaired Mann–Whitney U test (****P < 0.0001). (K) eRNA
enrichment fold-change (Nutlin-3A versus DMSO conditions) as measured by GRO-seq Nutlin/DMSO at p53-bound regions that signiicantly increased
(Sig.) in MPRA transcriptional activity upon Nutlin treatment versus p53-bound regions that did not signiicantly increase (NS) in MPRA transcriptional
activity (*P < 0.05, **P < 0.01 by unpaired Mann–Whitney U test. (L) Spearman correlation analysis of eRNA enrichment (log2) at p53-bound CREs
relative to enrichment of p53 (log2) in a region ± 250 bp from the p53RE between eRNA enrichment and p53-enrichment at MPRA regions.
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The lentivirus-based system expresses eGFP under the con-
trol of a minimal promoter and a putative p53-dependent
CRE sequence (31). Each putative CREwas included in the
library with ive unique, 12 nucleotide barcodes encoded in
the 3′UTR of eGFP to allow a molecular readout of tran-
scriptional activity (Figure 1A). We selected 296 putative
p53 binding locations based on the presence of a canon-
ical p53 family binding motif (p53RE), distance from the
nearest transcriptional start site (<100 kb), and localization
within a DNAse hypersensitive site (DHS). The 20 bp p53
family motif was centered in a 100 bp fragment with 40 bp
of lanking genomic context on each side. We also included
196 p53-independent and constitutively active CREs as de-
termined by FANTOMConsortiumCAGEdata as positive
controls of CRE activity (50). These sequences were cloned
into the lentiviral plasmid backbone pLS-MP as described
in the Methods and similar to previously described MPRA
designs (31).
We then examined the activity of our putative CREs us-
ing the model human colon carcinoma cell line HCT116
which is well-suited for studying p53-dependent transcrip-
tional activity. Our 296 potential p53-dependent CREs clus-
tered into two groups based on p53 occupancy using ChIP-
seq data fromHCT116 cells (1). 169 out of 296 regions were
scored as p53 binding sites (peaks) byMACS2 (bound, Fig-
ure 1B, Model-based Analysis of ChIP-seq, (51)), whereas
127 regions lacked measurable p53 binding (unbound, Fig-
ure 1C). The average position weight matrix of the p53RE
for each of the clusters is highly similar (Figure 1D), how-
ever, the consensusmotif in p53-bound regionsmore closely
resembles the optimal p53 consensus motif than do p53-
unbound CREs (Figure 1E). CREs bound by p53 show
higher enrichment of canonical enhancer-associated his-
tone modiications H3K27ac (Figure 1F), H3K4me1 (Sup-
plemental Figure S1A), andH3K4me2 (Figure 1G) than do
those regions lacking p53 occupancy in HCT116 cells. The
promoter-associated histonemodiicationH3K4me3 is sim-
ilarly enriched across both p53 bound and unbound CREs
(Supplemental Figure S1B). p53-bound CREs are also
found in regions with higher DNAse-accessibility (Supple-
mental Figure S1C) and aremore enriched for the transcrip-
tion initiation-associated RNA polymerase II C-terminal
domain modiication serine 5 phosphorylation (Supple-
mental Figure S1D). Consistent with the increased oc-
cupancy of transcriptionally associated features, enhancer
RNA (eRNA) transcription is more prevalent at p53-bound
CREs relative to those lacking p53 binding (Figure 1H)
(1,2). These data suggest that CREs that are destined for
binding by p53 have higher DNA accessibility, are more
enriched for chromatin modiications associated with tran-
scription, and produce more eRNA under basal/DMSO-
treated conditions than those not bound by p53.
We then performed triplicate biological measurements of
p53-dependent CRE activity in HCT116 using our MPRA
approach.MPRA-transduced cells were treated for 6 h with
either DMSO or the MDM2 inhibitor Nutlin-3A and ex-
pressed RNA barcodes were deep sequenced as described
in Methods. Nutlin-3A leads to stabilization and activa-
tion of p53 at a similar level to what is seen with DNA
damaging agents like etoposide (Figure 2A) (52). Impor-
tantly, enhancer activity measurements across biological
replicates, treatment conditions, and cell lines were highly
correlated (Supplemental Figure S2). As expected from our
analysis of p53 occupancy, p53-bound CREs showed a
bulk Nutlin-3A-dependent increase in activity compared to
treatment with DMSO (Figure 1I, ****P < 0.0001, one-
way ANOVA). Unbound CRE activity was not affected
by Nutlin-3A treatment relative to DMSO and was sub-
stantially lower than p53-bound CREs (Figure 1I, ****P
< 0.0001, one-way ANOVA). Activity of the ubiquitous
CRE controls were unaffected by the induction of p53 by
Nutlin-3A (Supplemental Figure S3A). eRNA transcrip-
tion wasmore highly upregulated at p53-boundCREs upon
Nutlin-3A treatment than at unbound CREs (Figure 1J),
consistent with the observed Nutlin-3A-dependent increase
in p53-bound CRE activity (Figure 1I). CREs with signii-
cantly increasedMPRA activity uponNutlin-3A-treatment
had more robust eRNA induction (DMSO versus Nutlin-
3A) than CREs with lower activity (Figure 1K). However,
p53 enrichment is only weakly correlated with total eRNA
abundance at a given CRE suggesting that p53 occupancy
alone is not an indicator of eRNA transcription (Figure 1L
for Nutlin-3A-treated conditions, Supplemental Figure S4
for DMSO-treated conditions), as has been previously re-
ported (2,53,54). These data demonstrate that knownmark-
ers of transcriptional activity, including histone modiica-
tions and eRNA transcription (54), distinguish p53-bound
versus p53-unboud CREs, but that additional features con-
tribute to the activity of p53-bound CREs.
p53-bound CREs require direct-binding of p53 for Nutlin-3A-
induced activity
In order to determine if Nutlin-3A-induced activity of p53-
bound CREs is p53-dependent, we assessed transcriptional
activity in matched HCT116 TP53+/+ and TP53−/− cell
lines (Figure 2A). Nutlin-3A-induced activity of p53-bound
CREs was diminished in HCT116 TP53−/− cells suggest-
ing these enhancers are dependent on wild-type p53 (Fig-
ure 2B). As expected, ubiquitously expressed CRE controls
were unaffected by the loss of p53 expression (Supplemen-
tal Figure S3A). To test whether CRE activity is direct or
indirectly dependent on p53, we compared wild-type CRE
sequences to those with either the 20 bp p53RE (Mid) or the
entire CRE sequence (Scr) randomized (Figure 2C). As a
control for randomization, we fully scrambled the 196 ubiq-
uitous CRE control sequences while preserving GC con-
tent, leading to a loss of activity (P< 0.0001, one ANOVA,
Supplemental Figure S3B). Scrambling either the p53RE or
the entire CRE sequence abrogates Nutlin-3A-dependent
enhancer activity (Figure 2D, ****P < 0.0001, one-way
ANOVA). In aggregate, wild-type CREs aremore highly ac-
tive thanMid or Scr CREs, suggesting that p53 strongly in-
luences overall CRE activity (Figure 2D). Taken together,
these data suggest that Nutlin-3A-induced activity of CREs
requires direct binding of p53, in agreement with previous
observations (9,10).
Variation in lanking sequence context alters p53-dependent
CRE activity
Previous work suggests that p53-dependent CREs uniquely
work in a single-factor mechanism in which only the pres-
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Figure 2. (A) Immunoblotting for p53 (top) or GAPDH (bottom) expression in HCT116 p53+/+ or p53−/− colon carcinoma cells after 6 hours of
treatment with DMSO (D), 10 uM Nutlin-3A (N) or 100 uM etoposide (E). (B) Normalized transcriptional activity of the wild-type p53-bound regions
in either HCT116 p53+/+ or p53−/− cells after a 6-h treatment of either DMSO or 10 uM Nutlin-3A. Data are depicted as enrichment of the 3′UTR-
encoded barcode linked to each putative regulatory region normalized to the enrichment of that same sequence integrated into the genome and represent
the averages from three biological replicates of each condition (****P < 0.0001 using an ordinary one-way ANOVA). (C) Sequences within the wild-type
p53-bound regions from the MPRA (WT) were shufled (while preserving GC content) to alter either the 20 bp p53 binding site (Mid) or the entire 100 bp
MPRA sequence. (D) Normalized transcriptional activity of p53-bound sequences for the wild-type (WT), p53-binding site scramble (Mid), or the full
scramble (Scr) regions in HCT116 p53+/+ cells after a 6-h treatment of either DMSO or 10 uMNutlin-3A. Data are depicted as enrichment of the 3′UTR-
encoded barcode linked to each putative regulatory region normalized to the enrichment of that same sequence integrated into the genome and represent
the averages from three biological replicates of each condition (****P < 0.0001 by one-way ANOVA).
ence of p53 is required for activation of transcription (9).
Thus, this model implies that other transcription factors are
required for CRE activity. Similarly, analysis of DNA se-
quences lanking functional p53REs revealed no consistent
enrichment or requirement for other transcription factor
binding motifs or sequences outside of the p53RE (9,10).
Because this model represents a potential novel mechanism
for enhancer function and diverges from canonical CRE
models, we sought to directly test whether p53-dependent
CRE activity requires sequences or transcription factormo-
tifs outside of the p53RE.We systematically scrambled non-
overlapping 20 bp regions of each CRE starting at the 5′
end (Figure 3A). As previously discussed, we also included
controls where the p53RE and the entire CRE sequence
were randomized (Figure 3A). We then asked whether in-
dividual CRE variants had signiicantly different transcrip-
tional activity than their wild-type counterpart in Nutlin-
3A-treated, wild-type HCT116 cells. Both the Mid and Scr
variant CREs displayed signiicantly reduced activity rel-
ative to wild-type CREs (Figure 3B, P < 0.001, one-way
ANOVA), consistent with a loss of p53 binding and p53-
dependent transactivation. Overall, 93 Mid or Scr CRE
variants had statistically signiicant differential activity rela-
tive to the wild-type CRE, with 88 (95%) displaying reduced
activity when sequences were randomized (Figure 3C, one-
way ANOVA with Tukey HSD, P < 0.05). Only 1.5% of
Mid or Scr variants (5/338) had statistically increased ac-
tivity relative to the wild-type sequence (Figure 3C), with
two-ifth of those more active variants representing scram-
bled CRE sequences that generated a novel canonical p53
binding site. The remaining three variants possessed unique
combinations of TF motifs with increased activity relative
to the wild-type, p53RE-containing sequences. These data
suggest that, overall, disruption of the p53RE is suficient
to decrease CRE activity.
Scrambling DNA sequence lanking a p53RE does not
affect transcriptional activity in aggregate (Figure 3B, P
> 0.05, one-way ANOVA). However, individual CREs
have signiicantly altered transcriptional outputs when
context-speciic regions are scrambled (Figure 3D, one-way
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Figure 3. (A) Schematic depicting scrambling of 20 bp sequences within 100 bp p53-boundMPRA regions. Sequence scramblingwas performed to preserve
total GC content within the 20 bp scrambled region relative to the wild-type sequence. (B) Normalized transcriptional activity of the MPRA sequences
depicted in (A) in HCT116 p53+/+ cells after a 6-h treatment with 10 uM Nutlin-3A. Data are depicted as enrichment of the 3′UTR-encoded barcode
linked to each putative regulatory region normalized to the enrichment of that same sequence integrated into the genome and represent the averages
from three biological replicates of each condition. (***P < 0.001 using an ordinary one-way ANOVA). (C) Volcano plot of wild-type MPRA sequence
activity compared to Mid or Full scramble. Data are plotted as Fold Change (WT over scramble) versus –log10 P-value (from a one-way ANOVA with
Tukey post-hoc test). (D) Volcano plot of wild-type MPRA sequence activity compared to lanking scramble (L1, L2, R2 or R1). Data are plotted as Fold
Change (WT over scramble) versus –log10 P-value (from a one-way ANOVA with Tukey post-hoc test). (E) Jitter plot depicting CRE activity values for
wild-type p53-bound CREs (in the Nutlin-3A-treated condition) for those variants with increased (up) or decreased (down) activity relative to wild-type.
P-value represents the result of an unpaired Mann–Whitney U test (****P< 0.0001). (F) Number of CRE variants per position that signiicantly increase
or decrease in MPRA transcriptional activity compared to WT sequences (*P < 0.05, ***P < 0.001, ****P < 0.0001 by Fisher Exact Test). (G) Heatmap
of transcription factor motif enrichment across 100 bp of the 169 p53-bound MPRA regions in the current study. Data represent a per base pair score
for the presence of JASPAR-derived transcription factor motifs (P < 0.0001, corresponding to a JASPAR score of 400 or greater). Regions are centered
on the putative p53 family response element. (G) Median values and the interquartile range are depicted in red. (H) Jitter plot representing the number
of JASPAR-derived transcription factor motifs lanking the p53RE of the p53-bound CRE (P < 0.0001, corresponding to a JASPAR score of 400 or
greater). Regions are centered on the putative p53 family response element (p53RE) and are extended –250 bp and +250 bp upstream. (I) Normalized
transcriptional activity of theWT,Mid or R2 version of Region 36/CCNG1 from theMPRA in HCT116 p53+/+ cells after 6 h of either DMSO or 10 uM
Nutlin-3A treatment. (****P < 0.0001 using an ordinary one-way ANOVA). (J) Normalized Luciferase activity of either wild-type or R2-scrambled
Region 36/CCNG1 sequence cloned upstream of a minimal promoter and driving expression of irely luciferase in either HCT116 p53+/+ or p53−/−
colon carcinoma cells. Firely luciferase values were normalized to those of Renilla luciferase driven by a CMV promoter and co-transfected with the
candidate Firely plasmid (**P< 0.01, ****P< 0.0001 using an ordinary one-way ANOVA) (K) Normalized transcriptional activity of the WT, L2, Mid or
R1 version of the TP53TG1 CRE from theMPRA inHCT116 p53+/+ cells after 6 h of either DMSO or 10 uMNutlin-3A treatment (**P< 0.01, ****P<
0.0001 using an ordinary one-way ANOVA). (L) Normalized Luciferase activity of either wild-type, L2, or R1-scrambled TP53TG1 CRE sequence cloned
upstream of a minimal promoter and driving expression of irely luciferase in either HCT116 p53+/+ or p53−/− colon carcinoma cells. Firely luciferase
values were normalized to those of Renilla luciferase driven by a CMV promoter and co-transfected with the candidate Firely plasmid (****P < 0.0001
by one-way ANOVA).
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ANOVA with Tukey HSD, P < 0.05). Variants with de-
creased p53-dependent CRE activity have wild-type coun-
terparts with higher expression values than compared to
those variants with increased activity (Figure 3E, P <
0.0001, Mann–Whitney U test). We then wanted to deter-
mine whether the position of the scrambled sequence rela-
tive to the p53RE inluenced the change in CRE activity by
examining the proportion of signiicantly upregulated and
downregulated CREs at each position. The Mid position,
containing a p53RE, was more strongly associated with de-
creased CRE activity upon scrambling relative to any other
position (Figure 3F, Fisher’s Exact Test), consistent with a
loss of p53-mediated activation. The R1 position (20–40 bp
3′ of the p53 RE) had a larger number of variants with dis-
playing signiicantly different activity than wild-type than
any of the other lanking region variants (Fisher’s Exact
Test, P< 0.05 for L1, L2 and R2), although the underlying
mechanism for this observation is unclear. These data sug-
gest that DNA elements important for CRE function can
be found in any position relative to the p53RE and that lo-
cal context and DNA sequence content may play key roles
in p53-bound CRE activity.
Previous analyses of local sequence context at p53-bound
CREs suggested a lack of enrichment of transcription fac-
tor motifs, besides the p53 RE, that might inluence CRE
activity (10). Our MPRA approach demonstrates that se-
quences lanking p53RE can contribute to CRE activity
(Figure 3D), but the context and content of DNA se-
quences inluencing p53-bound CRE activity is unclear.
Therefore, to determine whether the scrambling of lanking
sequences might disrupt speciic DNA-encoded informa-
tion, like transcription factor motifs, we undertook a series
of motif enrichment analyses on wild-type and scrambled
sequences. First, we examined the genome-wide enrichment
of known transcription factor motifs across p53-bound
CREs using HOMER (37). Expectedly, p53 family motifs
were highly enriched in the MPRA regions relative to size
and GC-content matched genomic regions (Supplemental
Table S6). We also observed statistically signiicant (Bon-
ferroni q value < 0.05) enrichment of other known tran-
scription factor motifs, including those in the AP-1, GATA
and ETS families (Supplemental Table S6). The observed
enrichment of transcription factor motifs near p53RE is
similar in a group of 1149 consensus p53 binding sites (9).
Of note, a wider range of transcription factor families are
represented in this consensus set of p53 binding sites, likely
due to the increase in number and length of surveyed re-
gions included in the analysis (±250 bp from p53RE) (Sup-
plemental Table S7, Supplemental Figure S5, Figure 3H).
In order to account for potential bias in a single motif en-
richment strategy, we also used gimmeMotifs (29) and the
JASPAR vertebrate transcription factor database (45) to
identify the position of transcription factor motifs relative
to the p53RE. p53-bound CREs are enriched for lanking
transcription factor motifs (Figure 3G and H) with a me-
dian of 18 distinct motifs found per p53-bound CRE (Fig-
ure 3H). Examination of transcription factor chromatin im-
munoprecipitation (ChIP) data from the Cistrome Browser
(41) suggests that numerous transcription factors are likely
to occupy our group of p53-bound CREs (Supplemental
Figure S6). Thus, our data suggests that regions proximal to
p53REs are enriched for transcription factor bindingmotifs
that may be involved in p53-dependent CRE activity.
We then focused exclusively on CRE variants that dis-
played reduced activity relative to the wild-type CRE se-
quence to better understand how lanking sequence con-
text might affect p53-dependent CRE activity. Our ratio-
nale was to identify potential transcription factors or func-
tional DNA elements that facilitate p53-dependent tran-
scriptional activity. The 47 p53-bound CREs with reduced
activity (Figure 3D) had a median loss of two JASPAR-
deined TF motifs relative to the wild-type sequence (Sup-
plemental Figure S7A). TF motif enrichment demonstrates
that the AP-1 family motif is enriched in WT sequences
and depleted from scrambled CREs (Supplemental Table
S8), being lost from 17% of CREs with reduced activity.
AP-1 family factors have wide-ranging roles in transcrip-
tion regulation, including mediating chromatin accessibil-
ity at CREs (55–57). Overall, motifs for 95 different TFs
are lost within the 47 scrambled REs with reduced activ-
ity, including AP-1, GATA, SP1 and ETS family members
(Supplemental Table S9). Loss of activity is not correlated
with loss of canonical transcription initiation sequences,
like the INR element (Supplemental Figure S7B) (58–61).
These data, taken together, suggest that loss of a broad set
of transcription factor motifs lanking p53RE can inluence
p53-dependent CRE activity.
We then moved to validate our observation that alter-
ing TF motifs lanking p53RE could reduce p53-dependent
CRE activity. We irst examined a CRE localized within the
irst intron of theCCNG1 gene that is induced uponNutlin-
3A treatment in a p53-dependent manner (Figure 3I). This
activity is abrogated when either the p53RE or the 3′ adja-
cent 20bp region are scrambled (positionR2, Figure 3I).We
observe similar results for a putative CRE localized within
the second intron of TP53TG1 where scrambling either the
5′ adjacent 20 or 40 bp downstream of the p53RE (Fig-
ure 3K) leads to diminished p53-dependent CRE activity.
We then sought to validate these MPRA results by utilizing
a standard Luciferase reporter-based assay of CRE activ-
ity. In contrast to the 100bp sequence tested in the MPRA,
we assessed the activity of a larger sequence encompassing
an entire region of DNase hypersensitivity (DHS) as de-
termined by ENCODE. DHS are putative regulatory re-
gions often possessing transcriptional activity (43). Both
the CCNG1 and TP53TG1 wild-type CREs are dependent
on p53 for full activity (Figure 3J, L, p53+/+), consistent
with the MPRA data. We conirmed that lanking region
variants with loss of activity in the MPRA displayed a sim-
ilar reduction of activity in traditional luciferase enhancer
assays (Figure 3J, L), suggesting our MPRA results are not
an artifact of the restricted sequence size (100 bp) or dif-
ferences in assay conditions. Under DMSO treated condi-
tions, CCNG1 and TP53TG1 CRE activity is reduced in ei-
ther p53-depleted cells (Figure 3J,L) or in the p53RE mu-
tant (mid) relative to the wild-type sequence (Figure 3I, K).
These results are likely indicative of either basal p53 activity
and genomic occupancy in unstimulated cells (10) or that
a population of cells is experiencing intrinsic stress, such
as DNA damage during S phase (62). For the CCNG1 en-
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/n
a
r/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/n
a
r/g
k
a
a
1
4
7
/5
7
8
1
2
0
6
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 0
9
 M
a
rc
h
 2
0
2
0
Nucleic Acids Research, 2020 11
hancer, loss of activity in theR2 variant is further reduced in
the absence of p53 (Figure 3J, P< 0.01, one-way ANOVA),
suggesting potential combinatorial activity of p53 and the
wild-type R2 sequence within the CCNG1 CRE. This com-
binatorial activity was not observed for TP53TG1, as the
wild-type CRE and the L2 and R1 variants have similar
activity in cells lacking p53 (Figure 3L). data suggest that
p53-dependent CREs require different sequences and mo-
tifs, and potentially TFs, lanking the p53RE for optimal
activity.
An SP1/KLF family motif is required for p53-dependent ac-
tivity of the CCNG1 CRE
We continued investigating the role of lanking DNA se-
quences on p53-dependent CRE activity by further exam-
ining the CCNG1 CRE. Both the DNA sequence within
the R2 position and the p53RE are highly conserved across
vertebrates suggesting that this region may have a con-
served functional regulatory role (Figure 4A). The p53-
dependence of the CCNG1 CRE is similar across human
cell types, as the R2 variant leads to a similar reduction in
enhancer activity relative to the wild-type sequence when
assayed in the non-transformed human cell line MCF10A
(Figure 4B). We then assessed the activity of the wild-type
and R2 variantCCNG1CREs in Trp53+/+ and Trp53−/−
mouse embryonic ibroblasts (MEFs). The R2 variant has
reduced activity compared to the wild-type CCNG1 CRE
in both wild-type and p53-deicient MEFs consistent with
our observations in human cell lines (Figure 4C, D). In or-
der to determine if the decrease in CCNG1 CRE activity
via R2 scrambling is due to a loss of the wild-type sequence
or a gain of function from the scrambled sequence, we cre-
ated a second R2 variant (R2*) that preserves GC content
but is further randomized from thewild-type sequence (Fig-
ure 4A). Both R2 and R2* variants lead to loss of CCNG1
CRE activity relative to wild-type and are further reduced
in the absence of p53 (Figure 4E). These results suggest that
20 bp lanking the p53RE within CCNG1 are required for
p53-dependent CRE activity. The 20 bp immediately down-
stream of the p53REwithinCCNG1 enhancer contains sev-
eral known transcription factor motifs based on analysis
from JASPAR (45), suggesting that the loss of activity may
be due to a loss of TF binding. The highest-scoring tran-
scription factor motif from JASPAR are for members of the
SP1/KLF family, and this G-rich motif is highly conserved
across vertebrates (Figure 4F-G). We therefore made sin-
gle base-pair mutations in the most conserved G3 and G4
residues of the SP1/KLF motif (Figure 4F, G) and asked
whether loss of these residues was suficient to reduce CRE
activity (63). Consistent with scrambling the entire 20 bpR2
region, mutation of either the G3 or G4 position within the
SP1/KLF motif severely diminishes transcriptional output
in both wild-type and p53-deicient cell lines (Figure 4H, I).
The additional reduction in CRE activity in p53-deicient
cells seen in SP1/KLFmotif variants suggests this region is
functionally important independent of p53. Taken together,
these data suggest that CCNG1 CRE activity requires both
p53 and a regulatory motif belonging to the SP1/KLF fam-
ily.
Loss of the SP1/KLF motif leads to reduced CCNG1 tran-
scription and reduced p53 binding
Thus far, our data indicate that the p53-dependent CCNG1
CRE also requires key DNA sequences lanking the p53RE
and that these DNA sequences likely represents a binding
motif for the SP1/KLF family. Therefore, we assessed the
role of the p53RE and the R2 position sequence in their na-
tive genomic contexts using CRISPR/Cas9-mediated mu-
tagenesis (Figure 5A). Guide RNA sequences were tar-
geted to either the p53RE, the R2 position, or the L2 po-
sition, which is 5′ adjacent to the p53RE, generating a
population of indel mutations (Figure 5A, Supplemental
Table S4). Targeting of the p53RE substantially reduced
endogenous CCNG1 mRNA abundance relative to non-
targeted Cas9 cells (Figure 5B, P < 0.0001). Consistent
with in vitro observations of CCNG1 enhancer activity,
mutations within the R2 position reduce CCNG1 mRNA
levels, albeit not as severely as mutations in the p53RE
(Figure 5B, P < 0.0001). As a control for sequence vari-
ants proximal to the p53RE, we generated indel muta-
tions in the L2 position which is found in the 20 bp im-
mediately preceding the p53RE. Targeting the L2 posi-
tion did not reduce endogenous CCNG1mRNA levels sug-
gesting that proximal DNA mutations are not suficient
to decrease transcriptional output (Figure 5B). Addition-
ally, the L2 control suggests that the act of targeting Cas9
to the CCNG1 intron does not affect CCNG1 transcrip-
tion on its own. These data further suggest that the p53RE
and sequences immediately downstream of the p53RE
are required for endogenous expression of the CCNG1
mRNA.
We generated a pool of indel mutations at three loca-
tions within the CCNG1 CRE, with mutations near the
p53RE and the R2 position leading to a reduction in en-
dogenous CCNG1 mRNA expression (Figure 5A, B). We
therefore coupled chromatin immunoprecipitation of p53
to amplicon sequencing to simultaneously determine in-
del mutations and their potential effect on p53 occupancy
at the CCNG1 CRE. As a control, we performed p53
ChIP under DMSO and Nutlin-3A-treated conditions on
HCT116 p53+/+ cells expressing wild-type Cas9 without a
gRNA to target it to DNA. We then ampliied a 150 bp re-
gion in theCCNG1CRE from the p53-immunoprecipitated
and input samples and sequenced them using Illumina ap-
proaches. We observed a 2.98-fold enrichment of the am-
pliied sequence in the Nutlin-3A-induced samples relative
to DMSO (Fig 5C, dotted lines), suggesting our amplicon
ChIP approach was valid.
We next performed ChIP experiments from DMSO and
Nutlin-3A-treated cell lines with Cas9 targeted to the
p53RE, L2 or R2 positions. Sixty six unique DNA vari-
ants were identiied within our pool when targeting Cas9 to
the p53RE within the CCNG1 CRE (Supplemental Table
S4, Figure 5C). As expected, the wild-type CCNG1 CRE
sequence and three variants with an intact p53RE were
enriched near the levels seen in the Cas9 control (Figure
3C, p53RE, black dots). Enrichment of p53 is below or
at DMSO levels when a p53RE is present but varies from
the wild-type version (Figure 5C, blue dots). As expected,
CCNG1 variants lacking a p53RE show a strong reduction
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Figure 4. (A) (top) Schematic of the 100 bp Region 36/CCNG1 enhancer. R2 position is annotated with the predicted motif ‘SP1/KLF’ 20 bp 3′ adjacent
to the p53RE and (bottom) per-basepair vertebrate phastCon score. (B) Normalized Luciferase activity (test sequence Firely versus constitutive Renilla)
for WT Region36/CCNG and the R2 version in the MCF10A mammary epithelial cell line (****P < 0.0001 paired t-test). (C) Normalized Luciferase
activity (test sequence Firely versus constitutive Renilla) for WT Region36/CCNG and the R2 version in either p53+/+ or p53−/− mouse embryonic
ibroblasts (*P < 0.05, paired t-test). (D) Rescaled view of p53−/− reporter assay data from (C) depicting normalized Luciferase data for the wild-type
or R2 version of the CCNG1 enhancer in p53−/− mouse embryonic ibroblasts (*P < 0.05, paired t-test). (E) Normalized luciferase activity for either
the wild-type, R2 or R2* version of the CCNG1 enhancer in HCT116 p53+/+ or p53−/− cells. (*** P < 0.001 by one-way ANOVA). (F) The canonical
Sp1/KLF family motif sequence in the CCNG1 enhancer as a transcription factor logo compared to the wild-type, G3, or G4 variants. This motif is
located within the R2 site of the CCNG1 CRE, between 0 and 20 bp from the p53 response element. (G) phyloP vertebrate conservation of the Sp1/KLF
family motif within the wild-type CCNG1 enhancer sequence showing high conservation at the G3 and G4 positions. Normalized enhancer activity for
the minimal promoter only (MP), WT, G2 or G3 CCNG1 variants in (H) HCT116 p53+/+ or (I) HCT116 p53−/− cells (**P < 0.01, ****P< 0.0001, by
one-way ANOVA).
in p53 binding. Variants proximal to the p53RE generally
reduced p53 binding to the level of DMSO treatment (no
enrichment), but many variants were depleted to the level
seen when the p53RE was mutated (Figure 5C). These data
are consistent with data showing that Cas9-induced muta-
tions proximal to GATA1 binding sites alter GATA1 occu-
pancy (64). None of the R2 mutations identiied contained
variants within the p53RE; however, when the conserved
SP1/KLFmotif wasmutated or lost, p53 occupancywas re-
duced relative to the presence of an intact motif (Figure 5C
(green dots), D, P < 0.01). Our ChIP-based approach sug-
gested that sequence variation lanking a p53RE can alter
in vivo p53 binding in a context-dependent manner. We also
performed electrophoretic mobility shift assays (EMSA) to
better understand the effect of lanking sequence variation
on p53 binding to p53RE. Increasing concentrations of re-
combinant p53 were combined with 60 bp double-stranded
DNA fragments representing the wild-typeCCNG1 p53RE
and either the L2 or R2 variants from the original MPRA
experiment (Figure 5E). The R2 variant had a modest, but
statistically signiicant, increase in Kd relative to either the
wild-type or L2 variants (Figure 5F). The reduction in p53
binding observed in the R2 variant by EMSA is consis-
tent with our results from the in vivo variant ChIP exper-
iment as well as the reduced p53-dependent transcription
of endogenous CCNG1. Surprisingly, although a number
of L2 variants had reduced p53 binding in vivo, we ob-
served similar p53 binding afinities for both the wild-type
and L2 sequences by EMSA (Figure 5F). The fully ran-
domized L2 variant does not affect p53-dependent CRE ac-
tivity or affect p53 binding in vitro, suggesting that loss of
p53 binding observed in vivo for speciic L2 variants may be
context-speciic. These data, along with our examination of
endogenous CCNG1 mRNA expression, indicate that the
speciic sequences proximal to the p53RE in the CCNG1
enhancer, which includes an SP1/KLF family motif, leads
to increased p53 occupancy and higher CCNG1mRNA ex-
pression.
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Figure 5. (A) Schematic depicting strategy to introduce insertion-deletion (indels) mutations into the native CCNG1 locus in HCT116 cell lines. Pools of
indel-containing cells were then used for measurement of CCNG1 mRNA expression and for analysis of p53 binding by ChIP-sequencing. (B) qRT-PCR
data of CCNG1 mRNA expression in control (WT Cas9), L2, p53RE or R2-targeted Cas9 experiments after 6 h of DMSO or 10uMNutlin-3A treatment
in HCT116 p53+/+ cell lines (****P < 0.0001, by one-way ANOVA). (C) Jitter plot of p53 ChIP-enrichment for each Cas9-induced mutation at the
native CCNG1 enhancer. Black dots represent genetic variants that retain a wild-type p53 response element motif, while red dots are genetic variants with
a mutated p53 response-element. Green dots represent sequences with a mutated or missing ‘SP1/KLF’ motif. Dashed line represents p53 ChIP/Input
enrichment (log2) for the control cell line after 6 h ofNutlin-3A treatment. (D) Comparison of p53ChIP enrichment from variants with either a canonical or
mutated Sp1/KLF family motif from the R2-targeted Cas9 experiment (red line is the median, **P < 0.01, unpaired t-test). (E) Electrophoretic Mobility
Shift Assay (EMSA) for recombinant p53 bound to the wild type, L2 or R2 variant of the CCNG1 cis-regulatory element DNA sequence. Images are
representative of four independent biological replicates. (F) Quantiication of EMSA experiment in (E) performed as described in Materials and Methods.
Fitted curves were itted using a two-site binding model (Hill equation; Hill coeficient = 2) using a non-linear regression.
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p53-dependent transcription of GDF15 requires regulatory
factors at two separate distal CREs
Data fromourMPRAapproach and follow-up experiments
demonstrate that p53-dependent transcriptional activity at
CREs is altered when sequences lanking the p53RE are
perturbed. The CREs regulating CCNG1 (Figure 3I, J) and
TP53TG1 (Figure 3K, L) are intragenic or proximal to
the gene promoter similar to the majority of known p53-
bound CREs directly controlling downstream gene expres-
sion (1,65). In order to better understand the regulatory po-
tential and mechanisms of gene distal p53 binding events,
we searched our MPRA dataset for p53-dependent CREs
distal to the promoters of known p53 target genes. One such
region is approximately 11kb upstream of GDF15, which
is well-characterized p53 target gene (2,66). As predicted,
basal and induced GDF15 expression is strongly dependent
on p53 (Figure 6F). GDF15 has also recently been iden-
tiied as a key modulator of inlammatory and metabolic
responses (26,27), but the CREs key to regulation after
p53 activation are known. This putative CRE (called E2)
is enriched with the histone modiications H3K27ac and
H3K4me2 and depleted for H3K4me3, a pattern strongly
associatedwith transcriptional CREs. p53 is strongly bound
to this region in vivo (Figure 6A). While examining the ge-
nomic context of this putative enhancer, we identiied a
second putative p53-bound CRE approximately 20kb up-
stream ofGDF15 in the 3′UTR of the PGPEP1 gene, which
we deine as E1. Both p53-bound regions are enriched for
H3K27ac and H3K4me2 in the absence of p53 (Figure 6A)
suggesting potential CRE activity independent of p53. This
observation is consistent with recent reports of basal en-
hancerRNA transcription and histonemodiication enrich-
ment at potential CREs in the absence of p53 (2,35,53). We
therefore wanted to determine whether these p53-bound re-
gions act as CREs for the endogenous expression ofGDF15.
We took advantage of a recently described approach to in-
activate enhancers (67). In this approach, a catalytically in-
active form of Cas9 (dCas9) was fused to the transcrip-
tional repressor domain KRAB, and this strong repressor
was targeted to either a control region (an enhancer for
an unrelated gene, FGF2), the two p53-bound regions, or
the GDF15 promoter. Compared to the non-targeting con-
trol, targeting dCas9-KRAB to either p53-bound distal re-
gion (E1 or E2) reduced expression of endogenous GDF15
mRNA in both basal (DMSO) or p53-activated (Nutlin-
3A) conditions (Figure 6B). Repression of GDF15 mRNA
levels when targeting either E1 or E2 was similar to that of
targeting theGDF15 promoter region (Figure 6B). These re-
sults provide evidence that the E1 and E2 regions, bound by
p53, are likely CREs regulating the expression of GDF15.
We next wanted to determine whether potential se-
quences or transcription factors might regulate the activ-
ity of these p53-bound CREs for GDF15. We sought to use
the breadth of publicly available ChIP-seq datasets to iden-
tify potential transcription factors bound the GDF15 E1
CRE. Using information from the CISTROME database
(41), we found that ATF3, a member of the AP-1 fam-
ily of transcription factors, strongly binds to the GDF15
E1 CRE in HCT116 cells (Figure 6C). The summit of the
ATF3 binding event coincides with an ATF3 DNA motif,
∼125 bp downstream of the p53RE (Figure 6C). We there-
fore focused on ATF3 because of its previous association
as a positive regulator of p53 activity and its well-known
role as a modulator of the inlammatory response (28,68–
70), of which GDF15 is a central regulator (27). Using a
luciferase reporter approach, we assessed the activity of the
GDF15 E1 enhancer in wild-type, p53-deicient, or ATF3-
deicient HCT116 cells. Loss of either p53 or ATF3 leads
to a substantial reduction of E1 enhancer activity (Figure
6D). As expected by the lack of binding in vivo, the activity
of the GDF15 E2 enhancer was unaffected by the loss of
ATF3, whereas it is strongly dependent on p53 for activity
(Figure 6D, E). Interestingly, although GDF15 E2 contains
multiple AP-1 family motifs, it is not bound by or regulated
by AP-1member ATF3. Expression of endogenous GDF15
mRNA as determined by polyA+ RNAseq is reduced in ei-
ther p53 or ATF3-deicient HCT116 cells consistent with
in vivo binding and activity of ATF3 at the GDF15 E1 en-
hancer (Figure 6F). Taken together, our data indicate com-
binatorial activity of both p53 and ATF3 is required for ac-
tivity of the GDF15 E1 enhancer and that both the E1 and
E2 enhancer directly regulate expression of GDF15.
DISCUSSION
A number of high throughput analyses of p53 genomic
occupancy revealed that p53 predominantly binds to cis-
regulatory regions (CRE) like enhancers and promoters
(34,35,39). The ability of p53 to activate transcription is
well established, however, speciic molecular mechanisms
underlying p53 activity at CRE are less well studied. Here,
we describe the use of a massively parallel reporter assay
(MPRA) to characterize the effect of local sequence varia-
tion and transcription factormotifs on p53-dependentCRE
activity. Our results support the canonical model of p53 ac-
tivity where p53 primarily functions as a strong transcrip-
tional activator at cis-regulatory elements (CRE) (73). Fur-
ther, we conirmed that the p53 response element (p53RE)
is a strong predictor of p53-dependent transcriptional reg-
ulation as has been observed across multiple experimental
systems (8–10). We then examined the contribution of lo-
cal sequence context on enhancer activity by systematically
altering sequences lanking the p53RE (Figure 3A). Our re-
sults indicate that sequences outside of the core p53 binding
site are required for optimal transcriptional activation (Fig-
ure 3C). These functional sequences include both putative
and conirmed transcription factor binding motifs, suggest-
ing that p53 requires additional DNA-bound factors for its
ability to activate transcription through CREs.
Two recent MPRA studies proposed a novel ‘single-
factor’ model for CRE regulation by p53 (9,10). In this
model, p53 is solely responsible for transcriptional out-
put of an individual p53-bound CRE and does not require
other transcription factors. Our data suggest that loss of p53
through either genetic depletion or through alteration of a
p53RE sequence severely diminishes p53-dependent CRE
activity (Figure 2B, D). Therefore, our data support the
necessity of p53 for stimulus-dependent activation of p53-
bound enhancers in agreement with the single-factor model
(9,10). Conversely, our results also demonstrate that addi-
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Figure 6. (A) Genome browser view of the GDF15 locus showing p53, H3K4me3, H3K27ac, and H3K4me2 enrichment in HCT116 p53+/+ or HCT116
p53−/− cell lines. E1= enhancer 1, E2= enhancer 2, and P= GDF15 promoter. Grey shaded boxes are placed over the E1 and E2 regions. (B) qRT-PCR
relative expression of GDF15 mRNA in control, promoter, E1, or E2-targeted dCas-KRAB-expressing HCT116 p53+/+ cells treated with either DMSO
(D) or 10uM Nutlin-3A (N) for 6 hours. (**** P < 0.0001, one-way ANOVA). (C) Genome browser view of the GDF15 E1 region showing ChIP-seq
enrichment of p53, ATF3, H3K4me3, H3K27ac or H3K4me2. DHS = DNAse hypersensitive site. Normalized Luciferse activity (relative to minimal
promoter only) of the GDF15 E1 enhancer (D) or the GDF15 E2 enhancer (E) in wild-type, p53−/− or ATF3−/− HCT116 colon carcinoma cells (*P
< 0.05, **P < 0.01, one-way ANOVA). (F) Reads per kilobase per million (RPKM) expression value of GDF15 mRNA from three replicates of polyA+
RNAseq of wild-type, p53−/− or ATF3−/− HCT116 treated for 6 h with either DMSO or 10 uM Nutlin-3A (***P < 0.001, ****P < 0.0001, one-way
ANOVA).
tional transcription factors can co-regulate p53-dependent
CRE activity. Our screening approach identiied numer-
ous motifs that positively or negatively affect CRE activ-
ity in a context-dependent manner (Figure 3C), including
those directly bound by other transcription factors. ATF3
binding to the GDF15 E1 enhancer is required for p53-
dependent CRE activity and endogenous GDF15 mRNA
expression (Figure 6D-E). Additionally, a CRE regulating
CCNG1 transcription requires both a p53RE and an ad-
jacent SP1/KLF family motif for activity (Figure 4E, F).
Loss of either motif diminishes native CCNG1 transcrip-
tion driven by the CRE (Figure 5A). p53 occupancy at the
CCNG1 enhancer is reduced when sequences lanking the
p53RE diverge from the wild type sequence as observed in
our in vivo ChIP experiments (Figure 5C). In vitro EMSA
experiments suggest that only variation in the 3′ adjacent
sequence, which contains the SP1/KLF motif, alters p53
binding afinity (Figure 5E-F). Similarly, only mutations
within the SP1/KLF motif affected endogenous CCNG1
mRNA levels (Figure 5B). CRE activity is reduced when
evolutionarily conserved residues in the SP1/KLFmotif are
altered in both wild type and p53-deicient cells. These data
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suggest the CCNG1 CRE requires both p53 and an addi-
tional factor bound to the SP1/KLF family motif for opti-
mal activity.
The requirement for other transcription factors in the
co-regulation of p53-dependent transcriptional activity at
CREs has not been characterized on a broad scale. Cer-
tainly, individual p53 CREs have been previously demon-
strated to require co-regulatory factors in reporter assays,
including the requirement for the p53RE and an AP-1 el-
ement bound by JunD for DNA damage-dependent acti-
vation of GADD45A transcription (74), amongst others.
A recent in vivo CRISPR/Cas9-screening approach iden-
tiied CEBP binding within a p53-dependent CRE re-
quired for optimal transcription ofCDKN1A and initiation
of senescence (22). Single nucleotide polymorphisms asso-
ciated with lung cancer risk found within a p53-regulated
CRE disrupt canonical transcription factor motifs, reduce
p53 binding, and alter expression of TNFRSF19 (7). In
this study, we identiied both ATF3 and a likely member
of the SP1/KLF family as co-regulatory transcription fac-
tors required for p53-dependent CRE activity. Of note, we
have not identiied speciic transcription factors that bind
to the CCNG1 or TP53TG1 CREs whose p53-dependent
activity is altered upon variation in lanking sequence. In
the case of CCNG1, the SP1/KLF family motif can be
bound by over 12 family members, most of which are ex-
pressed in the cell type (HCT116 colon carcinoma) used
in this study. Identiication of speciic transcription factors
binding to individual DNA elements is often challenging,
but updated approaches like the enhanced yeast 1-hybrid
or quantitative mass spectrometry methods are now possi-
ble (75,76). Importantly, we cannot rule out potential tran-
scription factor-independent roles for these motifs in regu-
lating p53-dependent CRE activity, such as the possibility
that DNA shape or nucleosome positioning changes in vivo
might be affected by changes in CRE sequence.
MPRAs are powerful tools for rapidly dissecting how se-
quence variation and context contributes to the activity of
CREs. Despite their power, speciic assay design choices
and the non-native genomic context of the MPRA ap-
proach might help to explain some of the discrepancies
between our work and previous reports (9,10). First, we
used a random, lentiviral-based genomic integration strat-
egy to deliver ourMPRA constructs, whereas previous p53-
based approaches have used transient, plasmid-based deliv-
ery (9,10). Genomic integration presumably allows for the
greater inluence of chromatin and higher-order genomic
structure which directly inluence transcription factor bind-
ing and activity (31). In direct comparison with episomal
DNA, the activity of integrated massively parallel reporter
constructs was more reproducible and more closely aligned
with expected activity based on CRE-associated biochem-
ical patterns like histone modiication and accessible chro-
matin in previous MPRA analyses (31). Second, our assay
was speciically designed to test the effect of sequence vari-
ation on p53-dependent CRE activity while post hoc com-
putational approaches were previously used to identify se-
quence features deining CRE activity. In both the primary
MPRA screen and in traditional plasmid-based enhancer
assays, we observed that variation in transcription factor
motif sequences lanking the p53RE could alter CRE ac-
tivity. Altering p53RE-adjacent TFmotif sequences did not
always alter CRE activity, suggesting sequence and context-
dependent effects (Figure 3D). Our MPRA approach was
limited to assaying the activity of short segments (100 bp)
of p53-bound CREs during the early phase of p53 activ-
ity and in only one cell type. Given that CREs regulate can
transcription in space and time, in addition to abundance,
additional cell types and contexts may ultimately reveal ad-
ditional TF requirements for p53-bound CREs. Further,
CREs are typically larger than 100 bp in length suggesting
additional transcription factors are likely involved in their
regulation that were not directly tested in this study.
Our data suggest that p53 activity at CREs often re-
quires additional transcription factors. However, we cannot
rule out that the recently proposed single factor model ex-
plains p53 activity at other locations, such as at the hun-
dreds of p53 binding sites that lack evidence of CRE-
associated histone modiications or features like eRNA
transcription (10,53,54). The most likely scenario is that
p53-bound CREs exist in a spectrum and have variable co-
factor requirements, such that both the single factor and
multi-factor model underlie the activity of different sets of
p53-bound CREs. Ultimately, additional work is needed to
dissect the speciic motif features, transcription factor re-
quirements, and context-dependence of p53-bound CREs
and how they function to enact the broad tumor suppres-
sor activity of p53.
Previous reports could not identify sequence-based fea-
tures beyond the p53RE that predicted p53-bound CRE ac-
tivity using machine learning and traditional motif enrich-
ment approaches (9,10).While accurate to say that there are
no other transcription factor motifs or sequence-features
that are as enriched as the p53RE (Supplemental Tables
S6 and S7), we ind that other transcription factor motifs
are well represented in the CREs we studied and within a
previously identiied core set of p53-bound CREs (Supple-
mental Tables S6 and S7). This includes overrepresentation
of the motif for the stress-dependent transcription factor
ATF3 (Supplemental Table S6), which binds to a number
of p53-dependent CREs and regulates activity of a CRE for
GDF15 (Figure 6D, E). ATF3 is a well-studied regulator of
p53-dependent transcription through control of p53 stabil-
ity and co-factor recruitment (28,68,69). Previous reports
clearly demonstrate that ATF3 can directly alter p53 sta-
bility and modulate p53 activity through interactions with
histone modifying enzymes (68,69,77). Our work uniquely
identiies a direct role for ATF3 DNA binding within a
p53-bound CRE and demonstrates a positive effect on p53-
dependent transcriptional activity. Given that ATF3 binds
to numerous p53-bound regions of the genome (28) and
their previously reported relationship, further examination
into the local interplay between p53 and ATF3 at DNA is
warranted.
p53 is a pioneer transcription factor and can me-
diate context-dependent chromatin remodeling at CREs
(10,35,53). Despite this activity, the large majority of p53
genomic binding events occur within regions that are ac-
cessible before p53 engagement (10,35,53,71), similar to
what is observed for glucocorticoid receptor binding (78).
These regions also contain chromatin modiications associ-
atedwith active CRE, includingH3K27ac andH3K4me1/2
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before p53 binding (1,35,53,71,72,72). Further, p53 deple-
tion does not alter basal CRE-associated chromatin modii-
cations or chromatin structure at the large majority of CRE
(35,53) suggesting that other transcription factors mediate
chromatin accessibility at most p53-bound CREs. Consis-
tent with this model, we observe enrichment of enhancer-
associated histone modiications H3K27ac and H3K4me2
at GDF15 E1 and E2 enhancers in the absence of p53 (Fig-
ure 6A.) Enhancer-derived RNA (eRNA) has also been
identiied as a strong predictor of transcription factor bind-
ing and CRE activity (54). Our data suggest that those
CREs with eRNA transcription are more likely to be bound
by p53 and are more likely to see p53-dependent gains
in enhancer activity (Figure 1H, J, K). In further support
of a multi-factor model, eRNA are transcribed from p53-
regulated CREs in the absence of p53 (2,53) suggesting
other transcription factors are bound and active as previ-
ously suggested (54). These data suggest that other factors
are likely responsible for establishing andmaintaining chro-
matin structure and basal activity at the majority of p53-
bound CREs. Recent reports suggest that p53 binding and
activity is strongly inluenced by cell type-speciic chromatin
accessibility (1,2,35), which itself is controlled by differen-
tial DNA binding transcription factor activity (11,12,79–
81). Indeed, we recently identiied p63, a p53 family mem-
ber, as a factor required for chromatin accessibility and ac-
tivity of certain p53-bound enhancers in epithelial cell types
(35). How p53 functions across various cell and tissue con-
texts is still a vital and open question, but recent reports
suggested that p53 binding and activity can be inluenced
by cell type suggest signiicant work remains to address the
broad scope of p53-dependent transcription (2,35,82).
We propose that the lack of a core set of commonly en-
riched transcription factors within p53-dependent CREs is
a potentially important regulatory feature of the p53 net-
work. By utilizing different sets of transcription factor co-
regulators, we hypothesize that global p53 transcriptional
activity is buffered against loss of any one regulatory part-
ner. This hypothesis for p53 is strongly reminiscent of the
‘billboard’ model seen at many Drosophila developmental
enhancers (11,18), whereby different combinations of fac-
tors can bind to a CRE and produce similar transcriptional
outputs. The lexible billboard model for p53-bound en-
hancers is also consistent with a recently proposed ‘dis-
tributed p53 network’ model whereby p53 transcriptionally
controls many genes, but that any one p53 target gene is dis-
pensable for tumor suppression (1).
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